Conclusion
Following a single dose up to 1,500 mg and multiple doses up to 750 mg, ibrexafungerp was safe, well-tolerated, and displayed a favorable PK profile in healthy Chinese subjects, which was similar to those in the previous studies conducted overseas. These results support further clinical development of ibrexafungerp in China.